Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, mycotic infections, and diabetic ketoacidosis occurr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2021-01, Vol.384 (2), p.129-139
Hauptverfasser: Bhatt, Deepak L, Szarek, Michael, Pitt, Bertram, Cannon, Christopher P, Leiter, Lawrence A, McGuire, Darren K, Lewis, Julia B, Riddle, Matthew C, Inzucchi, Silvio E, Kosiborod, Mikhail N, Cherney, David Z.I, Dwyer, Jamie P, Scirica, Benjamin M, Bailey, Clifford J, Díaz, Rafael, Ray, Kausik K, Udell, Jacob A, Lopes, Renato D, Lapuerta, Pablo, Steg, P. Gabriel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, mycotic infections, and diabetic ketoacidosis occurred with sotagliflozin.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2030186